FACULTY
Clinical Update on Alzheimer's Disease: Managed Care Perspectives
Activity Date: April 2007  — Activity Info: Volume 4, (4)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)

 
FULL DISCLOSURE POLICY AFFECTING CE ACTIVITIES
As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:

PROGRAM DIRECTOR
W. Nathan Rawls, PharmD
Professor, Department of Pharmacy
University of Tennessee College of Pharmacy
Clinical Pharmacy Specialist
Veterans Affairs Medical Center
Memphis, Tennessee
Dr Rawls reports having no financial or advisory relationships withcorporate organizations related to this activity.

PARTICIPATING FACULTY

Manju T. Beier, PharmD, FASCP
Senior Partner
Geriatric Consultant Resources, LLC
Clinical Associate Professor of Pharmacy
University of Michigan School of Pharmacy
Ann Arbor, Michigan
Dr Beier reports serving as a consultant for Eisai, Forest Laboratories, Novartis Pharmaceuticals, and Ortho-McNeil; and receiving honoraria from Eisai, Forest Laboratories, and Pfizer Inc.

Nicole Brandt, PharmD, CGP, BCPP, FASCP
Assistant Professor
Geriatric Pharmacotherapy
Director
Clinical and Educational Programs at the Peter Lamy Center on Drug Therapy and Aging
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland
Dr Brandt reports serving as a consultant for Forest Laboratories and Johnson & Johnson.

Howard Fillit, MD
Executive Director
The Institute for the Study of Aging, Inc.
New York, New York
Dr Fillit reports receiving grants/research support from Elan Pharmaceuticals and Forest Laboratories; and serving as a consultant for Neurochem, Neurologics, Ortho-McNeil, Pfizer Inc, and Sanofi-Aventis.

Notice: In accordance with ACPE Criteria for Quality, the audience is advised that an article in this CE activity contains reference(s) to unlabeled or unapproved uses of drugs or devices.

Dr Beier—cholinesterase inhibitors (moderate to severe Alzheimer’s disease).

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.




     
Home | Contact Us | View Account | Need Help?